16:20 EDT Dermata Therapeutics (DRMA) files to sell 10.01M shares of common stock for holders
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRMA:
- Dermata’s XYNGARI trial hits statistically significant difference at 4 weeks
- Buy Rating for Dermata Therapeutics: Promising Phase 3 Results and Strategic Advantages
- Dermata Therapeutics’ xyngari in acne meets all primary Phase 3 endpoints
- Dermata Therapeutics announces last patient visit in Phase 3 acne trial
- Dermata Therapeutics receives notice of acceptance for Australian patent